Global Benign Prostatic Hyperplasia Therapeutics Market Research Report 2024(Status and Outlook)

September 2024 | 125 pages | ID: G4CED2D37B32EN
Bosson Research

Abstracts

Report Overview:

Treatment of patients with obstructive benign prostatic hypertrophy (BPH) with the drug Finasteride leads to a moderately improved urinary flow, symptomatic improvement and halts the natural progress of the disease

The Global Benign Prostatic Hyperplasia Therapeutics Market Size was estimated at USD 6919.24 million in 2023 and is projected to reach USD 8456.32 million by 2029, exhibiting a CAGR of 3.40% during the forecast period.

This report provides a deep insight into the global Benign Prostatic Hyperplasia Therapeutics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Benign Prostatic Hyperplasia Therapeutics Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Benign Prostatic Hyperplasia Therapeutics market in any manner.

Global Benign Prostatic Hyperplasia Therapeutics Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Abbott Laboratories

Allergan plc

Astellas Pharma

Boehringer Ingelheim Pharma GmbH and Co. KG

Eli Lilly and Company

GlaxoSmithKline plc

Merck and Co.

Pfizer

Sanofi

Teva Pharmaceutical Industries Limited

Market Segmentation (by Type)

Alpha Blocker

5-Alpha Reductase Inhibitor

Phosphodiesterase-5 Inhibitor

Others

Market Segmentation (by Application)

Mono Drug Therapy

Combination Drug Therapy

Geographic Segmentation

• North America (USA, Canada, Mexico)
• Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
• South America (Brazil, Argentina, Columbia, Rest of South America)
• The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Benign Prostatic Hyperplasia Therapeutics Market
• Overview of the regional outlook of the Benign Prostatic Hyperplasia Therapeutics Market:

Key Reasons to Buy this Report:

• Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
• This enables you to anticipate market changes to remain ahead of your competitors
• You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
• The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Note: this report may need to undergo a final check or review and this could take about 48 hours.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Benign Prostatic Hyperplasia Therapeutics Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Benign Prostatic Hyperplasia Therapeutics
1.2 Key Market Segments
  1.2.1 Benign Prostatic Hyperplasia Therapeutics Segment by Type
  1.2.2 Benign Prostatic Hyperplasia Therapeutics Segment by Application
1.3 Methodology & Sources of Information
  1.3.1 Research Methodology
  1.3.2 Research Process
  1.3.3 Market Breakdown and Data Triangulation
  1.3.4 Base Year
  1.3.5 Report Assumptions & Caveats

2 BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET OVERVIEW

2.1 Global Market Overview
  2.1.1 Global Benign Prostatic Hyperplasia Therapeutics Market Size (M USD) Estimates and Forecasts (2019-2030)
  2.1.2 Global Benign Prostatic Hyperplasia Therapeutics Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region

3 BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET COMPETITIVE LANDSCAPE

3.1 Global Benign Prostatic Hyperplasia Therapeutics Sales by Manufacturers (2019-2024)
3.2 Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Manufacturers (2019-2024)
3.3 Benign Prostatic Hyperplasia Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Benign Prostatic Hyperplasia Therapeutics Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Benign Prostatic Hyperplasia Therapeutics Sales Sites, Area Served, Product Type
3.6 Benign Prostatic Hyperplasia Therapeutics Market Competitive Situation and Trends
  3.6.1 Benign Prostatic Hyperplasia Therapeutics Market Concentration Rate
  3.6.2 Global 5 and 10 Largest Benign Prostatic Hyperplasia Therapeutics Players Market Share by Revenue
  3.6.3 Mergers & Acquisitions, Expansion

4 BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS INDUSTRY CHAIN ANALYSIS

4.1 Benign Prostatic Hyperplasia Therapeutics Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET

5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
  5.5.1 New Product Developments
  5.5.2 Mergers & Acquisitions
  5.5.3 Expansions
  5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies

6 BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Type (2019-2024)
6.3 Global Benign Prostatic Hyperplasia Therapeutics Market Size Market Share by Type (2019-2024)
6.4 Global Benign Prostatic Hyperplasia Therapeutics Price by Type (2019-2024)

7 BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Benign Prostatic Hyperplasia Therapeutics Market Sales by Application (2019-2024)
7.3 Global Benign Prostatic Hyperplasia Therapeutics Market Size (M USD) by Application (2019-2024)
7.4 Global Benign Prostatic Hyperplasia Therapeutics Sales Growth Rate by Application (2019-2024)

8 BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET SEGMENTATION BY REGION

8.1 Global Benign Prostatic Hyperplasia Therapeutics Sales by Region
  8.1.1 Global Benign Prostatic Hyperplasia Therapeutics Sales by Region
  8.1.2 Global Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Region
8.2 North America
  8.2.1 North America Benign Prostatic Hyperplasia Therapeutics Sales by Country
  8.2.2 U.S.
  8.2.3 Canada
  8.2.4 Mexico
8.3 Europe
  8.3.1 Europe Benign Prostatic Hyperplasia Therapeutics Sales by Country
  8.3.2 Germany
  8.3.3 France
  8.3.4 U.K.
  8.3.5 Italy
  8.3.6 Russia
8.4 Asia Pacific
  8.4.1 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Sales by Region
  8.4.2 China
  8.4.3 Japan
  8.4.4 South Korea
  8.4.5 India
  8.4.6 Southeast Asia
8.5 South America
  8.5.1 South America Benign Prostatic Hyperplasia Therapeutics Sales by Country
  8.5.2 Brazil
  8.5.3 Argentina
  8.5.4 Columbia
8.6 Middle East and Africa
  8.6.1 Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Sales by Region
  8.6.2 Saudi Arabia
  8.6.3 UAE
  8.6.4 Egypt
  8.6.5 Nigeria
  8.6.6 South Africa

9 KEY COMPANIES PROFILE

9.1 Abbott Laboratories
  9.1.1 Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Basic Information
  9.1.2 Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Product Overview
  9.1.3 Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Product Market Performance
  9.1.4 Abbott Laboratories Business Overview
  9.1.5 Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics SWOT Analysis
  9.1.6 Abbott Laboratories Recent Developments
9.2 Allergan plc
  9.2.1 Allergan plc Benign Prostatic Hyperplasia Therapeutics Basic Information
  9.2.2 Allergan plc Benign Prostatic Hyperplasia Therapeutics Product Overview
  9.2.3 Allergan plc Benign Prostatic Hyperplasia Therapeutics Product Market Performance
  9.2.4 Allergan plc Business Overview
  9.2.5 Allergan plc Benign Prostatic Hyperplasia Therapeutics SWOT Analysis
  9.2.6 Allergan plc Recent Developments
9.3 Astellas Pharma
  9.3.1 Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Basic Information
  9.3.2 Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Product Overview
  9.3.3 Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Product Market Performance
  9.3.4 Astellas Pharma Benign Prostatic Hyperplasia Therapeutics SWOT Analysis
  9.3.5 Astellas Pharma Business Overview
  9.3.6 Astellas Pharma Recent Developments
9.4 Boehringer Ingelheim Pharma GmbH and Co. KG
  9.4.1 Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Basic Information
  9.4.2 Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Product Overview
  9.4.3 Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Product Market Performance
  9.4.4 Boehringer Ingelheim Pharma GmbH and Co. KG Business Overview
  9.4.5 Boehringer Ingelheim Pharma GmbH and Co. KG Recent Developments
9.5 Eli Lilly and Company
  9.5.1 Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Basic Information
  9.5.2 Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Product Overview
  9.5.3 Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Product Market Performance
  9.5.4 Eli Lilly and Company Business Overview
  9.5.5 Eli Lilly and Company Recent Developments
9.6 GlaxoSmithKline plc
  9.6.1 GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Basic Information
  9.6.2 GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Product Overview
  9.6.3 GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Product Market Performance
  9.6.4 GlaxoSmithKline plc Business Overview
  9.6.5 GlaxoSmithKline plc Recent Developments
9.7 Merck and Co.
  9.7.1 Merck and Co. Benign Prostatic Hyperplasia Therapeutics Basic Information
  9.7.2 Merck and Co. Benign Prostatic Hyperplasia Therapeutics Product Overview
  9.7.3 Merck and Co. Benign Prostatic Hyperplasia Therapeutics Product Market Performance
  9.7.4 Merck and Co. Business Overview
  9.7.5 Merck and Co. Recent Developments
9.8 Pfizer
  9.8.1 Pfizer Benign Prostatic Hyperplasia Therapeutics Basic Information
  9.8.2 Pfizer Benign Prostatic Hyperplasia Therapeutics Product Overview
  9.8.3 Pfizer Benign Prostatic Hyperplasia Therapeutics Product Market Performance
  9.8.4 Pfizer Business Overview
  9.8.5 Pfizer Recent Developments
9.9 Sanofi
  9.9.1 Sanofi Benign Prostatic Hyperplasia Therapeutics Basic Information
  9.9.2 Sanofi Benign Prostatic Hyperplasia Therapeutics Product Overview
  9.9.3 Sanofi Benign Prostatic Hyperplasia Therapeutics Product Market Performance
  9.9.4 Sanofi Business Overview
  9.9.5 Sanofi Recent Developments
9.10 Teva Pharmaceutical Industries Limited
  9.10.1 Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Basic Information
  9.10.2 Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Product Overview
  9.10.3 Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Product Market Performance
  9.10.4 Teva Pharmaceutical Industries Limited Business Overview
  9.10.5 Teva Pharmaceutical Industries Limited Recent Developments

10 BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS MARKET FORECAST BY REGION

10.1 Global Benign Prostatic Hyperplasia Therapeutics Market Size Forecast
10.2 Global Benign Prostatic Hyperplasia Therapeutics Market Forecast by Region
  10.2.1 North America Market Size Forecast by Country
  10.2.2 Europe Benign Prostatic Hyperplasia Therapeutics Market Size Forecast by Country
  10.2.3 Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Size Forecast by Region
  10.2.4 South America Benign Prostatic Hyperplasia Therapeutics Market Size Forecast by Country
  10.2.5 Middle East and Africa Forecasted Consumption of Benign Prostatic Hyperplasia Therapeutics by Country

11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)

11.1 Global Benign Prostatic Hyperplasia Therapeutics Market Forecast by Type (2025-2030)
  11.1.1 Global Forecasted Sales of Benign Prostatic Hyperplasia Therapeutics by Type (2025-2030)
  11.1.2 Global Benign Prostatic Hyperplasia Therapeutics Market Size Forecast by Type (2025-2030)
  11.1.3 Global Forecasted Price of Benign Prostatic Hyperplasia Therapeutics by Type (2025-2030)
11.2 Global Benign Prostatic Hyperplasia Therapeutics Market Forecast by Application (2025-2030)
  11.2.1 Global Benign Prostatic Hyperplasia Therapeutics Sales (K Units) Forecast by Application
  11.2.2 Global Benign Prostatic Hyperplasia Therapeutics Market Size (M USD) Forecast by Application (2025-2030)

12 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Benign Prostatic Hyperplasia Therapeutics Market Size Comparison by Region (M USD)
Table 5. Global Benign Prostatic Hyperplasia Therapeutics Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Benign Prostatic Hyperplasia Therapeutics Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia Therapeutics as of 2022)
Table 10. Global Market Benign Prostatic Hyperplasia Therapeutics Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Benign Prostatic Hyperplasia Therapeutics Sales Sites and Area Served
Table 12. Manufacturers Benign Prostatic Hyperplasia Therapeutics Product Type
Table 13. Global Benign Prostatic Hyperplasia Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Benign Prostatic Hyperplasia Therapeutics
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Benign Prostatic Hyperplasia Therapeutics Market Challenges
Table 22. Global Benign Prostatic Hyperplasia Therapeutics Sales by Type (K Units)
Table 23. Global Benign Prostatic Hyperplasia Therapeutics Market Size by Type (M USD)
Table 24. Global Benign Prostatic Hyperplasia Therapeutics Sales (K Units) by Type (2019-2024)
Table 25. Global Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Type (2019-2024)
Table 26. Global Benign Prostatic Hyperplasia Therapeutics Market Size (M USD) by Type (2019-2024)
Table 27. Global Benign Prostatic Hyperplasia Therapeutics Market Size Share by Type (2019-2024)
Table 28. Global Benign Prostatic Hyperplasia Therapeutics Price (USD/Unit) by Type (2019-2024)
Table 29. Global Benign Prostatic Hyperplasia Therapeutics Sales (K Units) by Application
Table 30. Global Benign Prostatic Hyperplasia Therapeutics Market Size by Application
Table 31. Global Benign Prostatic Hyperplasia Therapeutics Sales by Application (2019-2024) & (K Units)
Table 32. Global Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Application (2019-2024)
Table 33. Global Benign Prostatic Hyperplasia Therapeutics Sales by Application (2019-2024) & (M USD)
Table 34. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Application (2019-2024)
Table 35. Global Benign Prostatic Hyperplasia Therapeutics Sales Growth Rate by Application (2019-2024)
Table 36. Global Benign Prostatic Hyperplasia Therapeutics Sales by Region (2019-2024) & (K Units)
Table 37. Global Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Region (2019-2024)
Table 38. North America Benign Prostatic Hyperplasia Therapeutics Sales by Country (2019-2024) & (K Units)
Table 39. Europe Benign Prostatic Hyperplasia Therapeutics Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Benign Prostatic Hyperplasia Therapeutics Sales by Region (2019-2024) & (K Units)
Table 41. South America Benign Prostatic Hyperplasia Therapeutics Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Sales by Region (2019-2024) & (K Units)
Table 43. Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Basic Information
Table 44. Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Product Overview
Table 45. Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Abbott Laboratories Business Overview
Table 47. Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics SWOT Analysis
Table 48. Abbott Laboratories Recent Developments
Table 49. Allergan plc Benign Prostatic Hyperplasia Therapeutics Basic Information
Table 50. Allergan plc Benign Prostatic Hyperplasia Therapeutics Product Overview
Table 51. Allergan plc Benign Prostatic Hyperplasia Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Allergan plc Business Overview
Table 53. Allergan plc Benign Prostatic Hyperplasia Therapeutics SWOT Analysis
Table 54. Allergan plc Recent Developments
Table 55. Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Basic Information
Table 56. Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Product Overview
Table 57. Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Astellas Pharma Benign Prostatic Hyperplasia Therapeutics SWOT Analysis
Table 59. Astellas Pharma Business Overview
Table 60. Astellas Pharma Recent Developments
Table 61. Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Basic Information
Table 62. Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Product Overview
Table 63. Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Boehringer Ingelheim Pharma GmbH and Co. KG Business Overview
Table 65. Boehringer Ingelheim Pharma GmbH and Co. KG Recent Developments
Table 66. Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Basic Information
Table 67. Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Product Overview
Table 68. Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Eli Lilly and Company Business Overview
Table 70. Eli Lilly and Company Recent Developments
Table 71. GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Basic Information
Table 72. GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Product Overview
Table 73. GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. GlaxoSmithKline plc Business Overview
Table 75. GlaxoSmithKline plc Recent Developments
Table 76. Merck and Co. Benign Prostatic Hyperplasia Therapeutics Basic Information
Table 77. Merck and Co. Benign Prostatic Hyperplasia Therapeutics Product Overview
Table 78. Merck and Co. Benign Prostatic Hyperplasia Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Merck and Co. Business Overview
Table 80. Merck and Co. Recent Developments
Table 81. Pfizer Benign Prostatic Hyperplasia Therapeutics Basic Information
Table 82. Pfizer Benign Prostatic Hyperplasia Therapeutics Product Overview
Table 83. Pfizer Benign Prostatic Hyperplasia Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Pfizer Business Overview
Table 85. Pfizer Recent Developments
Table 86. Sanofi Benign Prostatic Hyperplasia Therapeutics Basic Information
Table 87. Sanofi Benign Prostatic Hyperplasia Therapeutics Product Overview
Table 88. Sanofi Benign Prostatic Hyperplasia Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Sanofi Business Overview
Table 90. Sanofi Recent Developments
Table 91. Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Basic Information
Table 92. Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Product Overview
Table 93. Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Teva Pharmaceutical Industries Limited Business Overview
Table 95. Teva Pharmaceutical Industries Limited Recent Developments
Table 96. Global Benign Prostatic Hyperplasia Therapeutics Sales Forecast by Region (2025-2030) & (K Units)
Table 97. Global Benign Prostatic Hyperplasia Therapeutics Market Size Forecast by Region (2025-2030) & (M USD)
Table 98. North America Benign Prostatic Hyperplasia Therapeutics Sales Forecast by Country (2025-2030) & (K Units)
Table 99. North America Benign Prostatic Hyperplasia Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 100. Europe Benign Prostatic Hyperplasia Therapeutics Sales Forecast by Country (2025-2030) & (K Units)
Table 101. Europe Benign Prostatic Hyperplasia Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 102. Asia Pacific Benign Prostatic Hyperplasia Therapeutics Sales Forecast by Region (2025-2030) & (K Units)
Table 103. Asia Pacific Benign Prostatic Hyperplasia Therapeutics Market Size Forecast by Region (2025-2030) & (M USD)
Table 104. South America Benign Prostatic Hyperplasia Therapeutics Sales Forecast by Country (2025-2030) & (K Units)
Table 105. South America Benign Prostatic Hyperplasia Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 106. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Consumption Forecast by Country (2025-2030) & (Units)
Table 107. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)
Table 108. Global Benign Prostatic Hyperplasia Therapeutics Sales Forecast by Type (2025-2030) & (K Units)
Table 109. Global Benign Prostatic Hyperplasia Therapeutics Market Size Forecast by Type (2025-2030) & (M USD)
Table 110. Global Benign Prostatic Hyperplasia Therapeutics Price Forecast by Type (2025-2030) & (USD/Unit)
Table 111. Global Benign Prostatic Hyperplasia Therapeutics Sales (K Units) Forecast by Application (2025-2030)
Table 112. Global Benign Prostatic Hyperplasia Therapeutics Market Size Forecast by Application (2025-2030) & (M USD)

List Of Figures

LIST OF FIGURES

Figure 1. Product Picture of Benign Prostatic Hyperplasia Therapeutics
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Benign Prostatic Hyperplasia Therapeutics Market Size (M USD), 2019-2030
Figure 5. Global Benign Prostatic Hyperplasia Therapeutics Market Size (M USD) (2019-2030)
Figure 6. Global Benign Prostatic Hyperplasia Therapeutics Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Benign Prostatic Hyperplasia Therapeutics Market Size by Country (M USD)
Figure 11. Benign Prostatic Hyperplasia Therapeutics Sales Share by Manufacturers in 2023
Figure 12. Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Manufacturers in 2023
Figure 13. Benign Prostatic Hyperplasia Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Benign Prostatic Hyperplasia Therapeutics Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Benign Prostatic Hyperplasia Therapeutics Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Type
Figure 18. Sales Market Share of Benign Prostatic Hyperplasia Therapeutics by Type (2019-2024)
Figure 19. Sales Market Share of Benign Prostatic Hyperplasia Therapeutics by Type in 2023
Figure 20. Market Size Share of Benign Prostatic Hyperplasia Therapeutics by Type (2019-2024)
Figure 21. Market Size Market Share of Benign Prostatic Hyperplasia Therapeutics by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Application
Figure 24. Global Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Application (2019-2024)
Figure 25. Global Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Application in 2023
Figure 26. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Application (2019-2024)
Figure 27. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Application in 2023
Figure 28. Global Benign Prostatic Hyperplasia Therapeutics Sales Growth Rate by Application (2019-2024)
Figure 29. Global Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Region (2019-2024)
Figure 30. North America Benign Prostatic Hyperplasia Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Country in 2023
Figure 32. U.S. Benign Prostatic Hyperplasia Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Benign Prostatic Hyperplasia Therapeutics Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Benign Prostatic Hyperplasia Therapeutics Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Benign Prostatic Hyperplasia Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Country in 2023
Figure 37. Germany Benign Prostatic Hyperplasia Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Benign Prostatic Hyperplasia Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Benign Prostatic Hyperplasia Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Benign Prostatic Hyperplasia Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Benign Prostatic Hyperplasia Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Benign Prostatic Hyperplasia Therapeutics Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Region in 2023
Figure 44. China Benign Prostatic Hyperplasia Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Benign Prostatic Hyperplasia Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Benign Prostatic Hyperplasia Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Benign Prostatic Hyperplasia Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Benign Prostatic Hyperplasia Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Benign Prostatic Hyperplasia Therapeutics Sales and Growth Rate (K Units)
Figure 50. South America Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Country in 2023
Figure 51. Brazil Benign Prostatic Hyperplasia Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Benign Prostatic Hyperplasia Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Benign Prostatic Hyperplasia Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Benign Prostatic Hyperplasia Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Benign Prostatic Hyperplasia Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Benign Prostatic Hyperplasia Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Benign Prostatic Hyperplasia Therapeutics Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Benign Prostatic Hyperplasia Therapeutics Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Benign Prostatic Hyperplasia Therapeutics Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Benign Prostatic Hyperplasia Therapeutics Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Benign Prostatic Hyperplasia Therapeutics Market Share Forecast by Type (2025-2030)
Figure 65. Global Benign Prostatic Hyperplasia Therapeutics Sales Forecast by Application (2025-2030)
Figure 66. Global Benign Prostatic Hyperplasia Therapeutics Market Share Forecast by Application (2025-2030)